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1. INTRODUCTION 
1.1 Ischemia-reperfusion injury 
Cardiovascular disease is the leading cause of death worldwide. In Norway, 6,203 men and 
7,286 women died of the disease in 2009, with approximately 40% of these deaths due to 
ischemic heart disease (www.ssb.no/dodsarsak/tab-2010-12-03-01.html). The most successful 
treatment for acute myocardial infarction is reperfusion by early thrombolytic therapy or 
primary percutaneous coronary intervention (PCI), although early reperfusion can also induce 
injury. This phenomenon is termed reperfusion injury, and was first described by Jennings et 
al. in 1960 [1]. Reperfusion injuries can explain up to 50% of the total infarct size in some 
animal models, and reperfusion injury may be one explanation as to why patients with 
myocardial infarction who receive early treatment still can experience reduced ventricular 
function and elevation of heart specific proteins in blood as a sign of myocardial infarction 
[2]. Reperfusion might be the cause of four types of cardiac injury: 1) myocardial stunning, 2) 
no-reflow, 3) reperfusion arrhythmias, and 4) lethal reperfusion injury [2].     
 
Acute coronary artery occlusion results in acute ST-elevation myocardial infarction (STEMI). 
This event can be modelled in animal hearts by prolonged ligation of a coronary artery 
followed by reperfusion. The ischemic phase causes a reduced oxygen and nutrition supply, in 
addition to the accumulation of waste products. The reperfusion phase results in oxidative 
stress, increased cytosolic and mitochondrial calcium, rapid resolution of intracellular acidosis 
and inflammation [2]. Cardiac cell death during ischemia-reperfusion injury occurs by 
necrosis, apoptosis and in association with autophagy [3].  
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Necrosis is unregulated cell death due to a depletion of cellular ATP, and causes the loss of 
plasma membrane integrity. Plasma membrane dysfunction results in a lack of sodium control 
and cell swelling by an increase in osmotic pressure, with swelling in organelles such as 
mitochondria also being characteristic. Without oxygen, mitochondria can no longer generate 
a proton gradient across the inner mitochondria membrane, and the mitochondria will 
gradually lose the proton gradient. The release of cellular contents into extracellular space 
causes inflammatory response and scar formation. In the clinic, this damage is used as a 
diagnostic tool by analysing troponin-t release from cardiac cells. If there is a release of 
troponin-t, this is an indication that the cardiac cells are damaged and there has been a cardiac 
infarction [2].  
 
An important mechanism that leads to the acceleration of a loss of energy production is the 
opening of the mitochondrial permeability transition pore (MPTP). MPTP is a non-selective 
channel in the inner mitochondrial membrane that only allows molecules less that 1.5 KDa to 
pass through. The molecular composition of the MPTP is still unsolved. Biochemical and 
pharmacological studies have proposed that the pore consists of a voltage-dependent anion 
channel (VADC) in the inner mitochondrial membrane, the adenine nucleotide translocase 
(ANT) in the outer mitochondrial membrane and cyclophilin-D (CypD) in the matrix, 
although genetic studies have seriously questioned the validity of this theory. The 
determination of the level of the MPTP opening by use of radiolabelled 2-deoxyglucose 
indicates that the MPTP remains closed during ischemia and opens within 5-10 min after 
reperfusion in isolated rat hearts [4]. The opening of the MPTP may be triggered by elevated 
calcium, oxidative stress, elevated phosphate concentration and adenine nucleotide depletion 
in the early ischemia-reperfusion period. The opening of the MPTP results in a loss of the 
electrical potential difference that normally exists across the inner mitochondrial membrane. 
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As a result, the mitochondria can no longer produce ATP regardless of oxygen presence and 
results in ATP depletion and mitochondrial swelling, which is an important part of necrosis 
[1; 5; 6].   
 
Apoptosis is an actively regulated form of cell death that is believed to partly depend on the 
presence of ATP. Apoptotic cells exhibit cytoplasmic shrinkage, plasma membrane blebbing, 
nuclear condensation, and later fragmentation of both the cytoplasm and nucleus into 
membrane-enclosed apoptotic bodies. Apoptosis is mediated by two pathways. The extrinsic 
pathway utilizes cell surface receptors, whereas the intrinsic pathway involves the 
mitochondria and endoplasmic reticulum. Both of these pathways lead to caspase activation, 
and have been shown to be critical in the pathogenesis of ischemia-reperfusion injury [7; 8]. 
Toxic stimuli such as ischemia-reperfusion injury, oxidative stress and cardiotoxic drugs 
induce the translocation and integration of the prodeath members of the Bcl2 family (e.g. Bax, 
Bak) into the outer mitochondrial membrane. These proteins permeabilize the outer 
mitochondrial membrane to an extent that allows the release of proapoptotic proteins from the 
intermembrane space, particularly cytochrome C. Cytochrome C binds to the cytosolic protein 
apaf1 and results in activation of caspase-9 and caspase-3 protease systems [5].  
 
In contrast to necrosis and apoptosis, autophagy is primarily a survival and recycling 
mechanism. Autophagy maintains the cell itself, but cell organelles such as mitochondria 
could be lost. Autophagy provides cells with amino acids, fatty acids and energy in times of 
nutritional deprivation, and is mediated by the formation of a double-membrane vesicle 
(autophagosome) that surrounds the material to be degraded. The autophagosome fuses with 
the lysosome to form an autophagolysosome, resulting in a lysosomal degradation of the 
cargo. Autophagy is induced during both permanent coronary occlusion and ischemia-
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reperfusion injury, though the underlying pathways and functional consequences appear to 
differ. There are data that suggest that during prolonged ischemia autophagy plays a 
protective role, while during reperfusion autophagy may be a cytotoxic agent, but further 
investigation is required to achieve a better understanding of this phenomenon [9]. 
 
1.2 Cardioprotection 
The heart can be protected against ischemia-reperfusion injury with both endogenous 
activation and pharmacological treatment. Endogenous protection means that the body itself 
can activate systems/pathways that lead to the protection of an organ. Pharmacological 
protection means that we can add a compound to the body and that this compound can protect 
an organ directly or by the activation of protective systems/pathways.  
 
Endogenous cardioprotection was first described by Murry et al. in 1986 [10]. Murry showed 
that short periods with ischemia and reperfusion before prolonged ischemia protected the 
heart, and this phenomenon is called ischemic preconditioning (IPC). Since 1986, many labs 
have been working with IPC, and there is now evidence that IPC is able to activate different 
pathways that converge on the mitochondria and modulate their function, including their 
involvement in both necrotic and apoptotic cell death. The cardioprotective capacity of IPC 
has been demonstrated in the human heart in several clinical presentations of ischemia-
reperfusion, including cardiac surgery, preinfarction angina and angioplasty [11-13].  
 
In 2003, Vinten-Johansen’s group [14] showed that short periods of ischemia and reperfusion 
after prolonged ischemia were cardioprotective, and this phenomenon was called ischemic 
postconditioning (IPOST). Today, there is good evidence that IPOST reduces ischemia-
reperfusion injury through activation of the RISK pathway (Fig 1.1 B), which mostly 
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converges on mitochondria to inhibit the MPTP. From 2003, there have only been a few small 
clinical trials with IPOST on humans. Staat et al. 2005 [15] reported that IPOST with four 
episodes of 1 min inflation-deflation of the angioplasty balloon performed within 1 min of 
reflow in patients with an acutely occluded coronary artery reduced the infarct size by 30-
40%. 
 
Pharmacological pre- and postconditioning have been attempted and have shown reduced 
ischemia-reperfusion injury. From a clinical perspective, pharmacological postconditioning 
has the greatest potential because of the time point. The use of MPTP inhibitors such as 
cyclosporine A (CsA) are the most studied in humans. In 2008, Piot et al. [16] tested whether 
CsA could represent a pharmacological alternative to IPOST in humans. They randomly 
assigned 58 patients, who presented with acute ST-elevation myocardial injury, to receive 
either an intravenous bolus of CsA or normal saline immediately before undergoing PCI. 
They found that CsA attenuated the infarct size by approximately 40%. For the time being, 
there is no pre- or postconditioning-based therapy that is routinely used in clinical medicine. 
Today, high potassium and hypothermia are used during open chest heart surgery as 
cardioprotective strategies. During PCI, there is no cardioprotective strategy in routine use 
today.   
 
Three different cardioprotective protein kinase programmes have been proposed to explain 
IPC, IPOST and pharmacological treatment: survival pathway, RISK pathway and JAK-
STAT pathway [17].  
 
The survival pathway (Fig 1.1 A) was proposed by Downey et al. [18], and has been recruited 
during the trigger and mediator phase of acute ischemic preconditioning or pharmacological 
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treatment. After activation of G-protein-coupled receptors by adenosine, bradykinin, opioids, 
etc., or receptors for peptides such as natriuretic peptides, phosphinositide 3 kinase 
(PI3K)/AKT is activated with the further downstream activation of NO formation, protein 
kinase B (PKB) and protein kinase C (PKC) activation. This leads to the activation of the 
mitoKATP-channel and reactive oxygen species (ROS) formation, thus resulting in p38 
mitogen-activated kinase and PKC activation, as well as inhibiting opening of the MPTP [17; 
18].  
 
The reperfusion injury salvage kinase pathway (RISK-pathway) (Fig 1.1 B) was proposed by 
Yellon and Baxter [19]. This pathway is recruited during early reperfusion with the execution 
phase of IPC and with IPOST. The activation of sarcolemmal G-protein-coupled receptors, or 
of receptors for growth factors, results in activation of PI3K/Akt and the extracellular 
regulated kinase system, with downstream p70 ribosomal protein S6 kinase (p70S6K) and 
glycogen synthase kinase 3β (GSK-3β) activation and the ultimate inhibition of the MPTP 
[17; 19].   
 
The JAK-STAT pathway (Fig. 1.1 C) was proposed by Lecour et al. [20] and Boengler et al. 
[21], and is recruited with IPC, delayed IPC and IPOST. After activation of sarcolemmal 
glycoprotein 130 (gp130) receptors or tumour necrosis factor-a receptor, the Janus-activated 
kinase (JAK) signal transducer and the activator of transcription (STAT) pathway are 




Figure 1.1: Protein kinase activation in cardioprotection, A - Survival pathway; B - RISK pathway, and C - JAK-
STAT pathway. Figure is a copy from Heusch et al. [17].  
 
In 2009, Garlid et al. [22] proposed that cardioprotective signals are transmitted to 
mitochondria by signalosomes, which are vesicular, multimolecular signalling complexes that 
are assembled in caveolae and deliver signals to the mitochondrial outer membrane (Fig 1.2). 
They proposed that the receptor-specific signalling platform is assembled in caveolae, and 
then separates and internalizes as a signalosome. The signalosome migrates via the 
cytoskeleton to mitochondria, where it binds to receptors on the mitochondrial outer 
membrane. The terminal kinase of the signalosome phosphorylates its specific receptor, which 
causes the signal to be transmitted across the mitochondrial outer membrane and 
intermembrane space to PKCε on the mitochondrial inner membrane. This is followed by the 
mitoKATP/mitoKCa-channel opening and inhibition of the MPTP.  
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Figure 1.2: Copy from Galid et al.[22], who proposed signal transmission by signalosome to mitochondria.    
 
1.3 Connexin 43 
Connexin 43 (Cx43) is the predominant protein forming gap junctions and non-junctional 
hemichannels in ventricular myocardium and myofibroblasts. The connexins have four 
transmembrane domains, two extracellular loops and cytoplasmic N-terminal and C-terminal 
domains. Many, but not all, connexins form channels without any particular selectivity for 
specific ions [23], and are permeable for small ions and molecules with a molecular weight up 




Figure 1.3: Schematical overview of Cx43 as hemichannels and gap junctions. Figure is a copy from Evans et al. 
[25].    
 
Gap junctions are specialized membrane areas that contain aggregates of intercellular 
channels connecting the cytoplasm of two adjacent cells. The gap junction channels allow 
electrical coupling, metabolic cooperation and the coordination of cell activities. Each gap 
junctional channel is composed of two end-to-end connected hexameric structures called 
hemichannels or connexons, one from each of the connected cells. These hexameric structures 
are formed by the connexin proteins, whereas the flux of molecules through the gap junction 
channels is determined by the chemical and electrical gradients between two connected cells. 
Moreover, the transfer of molecules between connected cells is also affected by the assembly 
and degradation of gap junctions [26] that essentially regulate the number of potentially active 
channels, in addition to their pore size and open probability [27]. Under resting conditions, 
gap junction channels are in an open state while hemichannels are predominantly in a closed 
state, and their gating is regulated, among other factors, by the phosphorylation status of the 
connexins [28].  
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There might be a different regulation of Cx43 hemichannels and full gap junction channels 
during ischemia. Whereas metabolic inhibition opens Cx43 hemichannels [29], ischemia 
induces the closure of gap junction channels, both when determined electrophysiologically 
[30] or by transfer of gap junction-permeable dyes [31; 32]. An increased cytosolic Ca2+ 
concentration, reduced ATP concentration, changes in the phosphorylation of Cx43 and 
acidification, all occurring during ischemia-reperfusion injury, close gap junction channels 
[33], whereas a decrease in extracellular Ca2+ concentration or changes in phosphorylation 
have been described to open Cx43 hemichannels [28]. It is possible that environmental 
conditions differentially modulate the response of Cx43 to ischemic conditions, although no 
clear explanation for such differences is available.  
 
Recent findings may indicate that Cx43 is important in ischemic preconditioning, which is 
demonstrated by a failure to protect Cx43-deficent (Cx43+/-) animals [34]. Also, hearts from 
animals with heart failure and hearts from old animals were resistant to IPC and showed 
decreased level of Cx43. Boengler et al. [35] showed that Cx43 was localized in the inner 
mitochondrial membrane of cardiac subsarcolemmal mitochondria (SSM). They found an 
increased amount of Cx43 in SSM after IPC, and they also suggested that mitochondrial Cx43 
forms a hemichannel-like structure in the inner mitochondrial membrane that functions as a 
positive regulator of the mitoKATP-channel during IPC [35; 36]. If present in the 
mitochondrial inner membranes, Cx43 hemichannels should normally be closed to inhibit 
mitochondrial uncoupling and loss of electrochemical gradients in a similar way as for MPTP. 
Under basal conditions, most Cx43 protein is found at the intercalated disks, whereas only 4% 
is localized in mitochondria and 8% in the cytosol. The rapid increase in mitochondrial Cx43 
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content in response to IPC indicates that it is due to changes in the intracellular kinetics of 
Cx43, rather than to increased protein synthesis [37].  
 
 
Figure 1.3: Scheme proposed by Ruiz-Meana et al. summarizing the potential roles of Cx43 in the 
pathophysiology of ischemia-reperfusion injury [37]. 
 
1.4 Pannexin 1 
In 2003, the mammalian pannexin gen family was cloned for the first time. It is homologous 
to the invertebrate gap junction protein, innexin [38]. Although there are structural similarities 
between connexins and pannexins, they appear to be two evolutionary distinct families [39]. 
In humans and other mammals, there are three pannexins: 1, 2 and 3, and Pannexin 1 (Panx1) 
is the most studied pannexin. Pannexins have the same membrane topology as connexions: 
four transmembrane domains, two extracellular loops, a cytoplasmic loop and cytosolic N-and 
C-termini [40]. Panx1 forms hemichannels in a number of cell types, and can be opened by 
ischemia-like conditions in pyramidal neurons [41]or by purinergic receptor stimulation in red 
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blood cells [42]. Panx1 only rarely forms gap junctions, and all reported cases have been in 
selective overexpression systems. Panx1 is widely expressed in the body [43], making it a 
potential candidate for hemichannel activities found in different cells and organs. Panx1 has 
also been found in ER and seems to form intracellular calcium-leak channels [44]. Vessey et 
al. [45; 46] have suggested that a brief period of ischemia-reperfusion induces the formation 
of pannexin-1/P2X7 channels, which then promotes the release of multiple cardioprotectants 
that mediate the protection of IPC and ischemic postconditioning. Karpuk et al. [47] revealed 
that Panx1 mimetic peptide 10Panx1 can block Panx1 hemichannels during inflammation in 
astrocytes.  
 
1.5 Hydrogen sulfide 
Hydrogen sulfide (H2S) is commonly recognized as a gas with an odour of rotten eggs. The 
toxicology of the gas has been known for many decades, and the physiological role was first 
proposed as late as in 1989 [48]. Today, hydrogen sulfide is termed as a gasotransmitter, 
together with nitric oxide (NO) and carbon monoxide (CO) (Fig 1.4). Gasotransmitters are 







Figure 1.4: Overview over endogenously produced gases in the cardiovascular system. Figure is modified from 
Calvert et al. [49] .  
 
Hydrogen sulfide is synthesized in mammalian tissues via endogenous enzymes and by 
nonenzymatic pathways. There is strong evidence that the cardiovascular system is an 
endogenous source of hydrogen sulfide generation. This evidence includes both the 
expression of hydrogen sulfide generating enzymes and the detection of hydrogen sulfide 
within these tissues [49]. There are three important enzymes that catalyze hydrogen sulfide 
production: cystathionine b-synthase (CBS), cystathionine g-lyase (CSE) and 3-
mercaptopyruvate sulfurtransferase (3MST) see Fig. 1.5. Hydrogen sulfide is detected in 
many tissues and in blood. In some reports, concentrations up to 160 μM in the brain and 100 
μM in blood are quoted, although the concentrations differ quite a bit from lab to lab [50]. 
There is still no gold-standard method for measuring hydrogen sulfide, and the reported 















2. AIMS OF THE STUDY 
The main aim of this thesis was to examine gap junctions, hemichannels and mitochondria 
during ischemia-reperfusion injury, and to try and use the knowledge obtained to develop new 
strategies for cardioprotection.  
 
The first sub-aim was to examine gap junction intercellular communication and hemichannel 
permeability during simulated ischemia, as well as to investigate changes in the 
phosphorylation of Cx43 during simulated ischemia and the importance of Cx43-
hemichannels in cell death. We also wanted to examine whether the channel protein pannexin 
1 protein was expressed in the heart, and if so, to demonstrate the subcellular localization.  
 
The second sub-aim was to test treatments to reduce ischemia-reperfusion injury, which is 
related to gap junctions and hemichannels. We aimed to investigate the underlying 
mechanisms and importance of mitochondria. Pretreatment with heptanol as an unspecific gap 
junction uncoupler, Gap 26 mimetic peptide as a specific Cx43-hemichannel blocker in early 










3. METHODOLOGICAL CONSIDERATIONS 
3.1 Isolated retrograde perfused rat hearts 
Oskar Langendorff was the first to perfuse an isolated heart in 1895 [51]. For the last 40-50 
years, isolated perfused hearts have been used on a large scale in cardiovascular research, 
with the method now established in many cardiovascular labs [1; 10; 17: 18; 19; 22; 37; 52; 
53]. By using this experimental model, we can examine the heart itself. The heart is not 
affected by changes in blood composition and neurotransmitters, in addition we are able to 
control the pre- and afterload. The advantage of the technique is also that it is easy to perfuse 
many hearts within a few days, and to test new hypotheses in a short period of time. All hearts 
are exposed to the same buffer, perfusion pressure, temperature and concentration of various 
chemicals. In the present thesis, the main end point was infarct/risk ratio, although the 
coronary flow, heart rate, left ventricular pressure and temperature were also measured. There 
are some technical challenges with the model when using ischemic injury as an end point. It is 
very important to get the heart to the perfusion rig quickly; if not, the heart can be 
accidentally exposed to ischemic preconditioning and the infarct size can be low. Regional 
ischemia is made by a suture and a snare, and it is important that this suture covers the 
coronary artery and that the snare is tightened enough so that ischemia is complete. It is 
important to take into consideration that this is an ex vivo model, and not an in vivo model, 
when conclusions are drawn. Chemical compounds used in the buffer may have changed their 
properties in blood, so to confirm findings in isolated perfused hearts, in vivo experiments 
have to be performed before treatment is adapted in a preclinical setting.       
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3.2 Cell cultures 
Fibroblasts are important cells in the heart, with the heart containing more fibroblasts than 
cardiac myocytes by number, but not by volume. Sixty-seventy percent of the cells in the 
human heart are cardiac fibroblasts, which are a key source of the components of the 
extracellular matrix that regulate the structure of the heart and hence the mechanical, chemical 
and electrical signals between the cellular and non-cellular components. Neonatal rat cardiac 
myofibroblasts have been used in this thesis, though caution should be taken in extrapolating 
results from these developmentally immature cells to those of the adult cardiac fibroblasts 
[54]. 
 
Gap junction intercellular communication was investigated by the microinjection of Lucifer 
yellow. Lucifer yellow is a non-toxic tracer that diffuses through gap junctions but does not 
cross the cell membrane. A limitation of microinjection is that only a few cells can be 
microinjected, and not at the same time. Thus, the technique is not convenient when a large 
number of cells need to be simultaneously monitored for intercellular communication. Scrape 
loading is another technique if there is a need for investigating a large number of cells [55], 
but we have not used this method in this thesis.   
 
Hemichannel permeability was also examined by the use of Lucifer yellow, which was added 
in the buffer/medium 2 min before the end of the experiment. Lucifer yellow diffused into 
cells if the hemichannels were opened, although a limitation of this method is that the cells 
lost the connection to the cell culture dish if they were exposed for too long a time to 
simulated ischemia or to very high concentrations of the oxygen scavenger, dithionite. 
Consequently, this may make it difficult to calculate the exact relationship between numbers 
of cells with open or closed hemichannels (underestimation). 
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3.3 Viability 
The measurement of infarct size in perfused rat hearts was performed at the end of the 
reperfusion period (120 min after ischemia). The heart was then perfused with 0.5-1 ml of 
0.5% Evans Blue to stain the non-ischemic tissue, and then frozen for 12-24 hours. Two mm 
transverse sections were incubated in 1% triphenyltetrazolium chloride (TTC) in PBS at 37 
degree for 15-20 min. The non-infarcted tissue was stained red, while the necrotic tissue 
remained unstained.  
 
Cell viability in cell cultures was measured by use of a viability kit from Promega. This kit 
contain MTS (3-(4,5 dimethylthiazol-2-ly)- 5-(3-carboxymethonyphenol)-2-(4-sulfophenyl)-
2H-tetrazolium). The kit demands an accurate control of the number of cells in the dish, as the 
change in colour may be too high or too low (outside detection limit) if not.  
 
Both of these methods are based on TTC/MTS being enzymatically reduced to a formazan 
product with colour (red or yellow) by dehydrogenases, which are most abundant in 
mitochondria. The staining intensity correlates with the number and functional activity of 
mitochondria [56]. Furthermore, these methods do not give an answer with respect to the type 
of cell death, apoptosis, necrosis or autophagy. 
 
3.4 Antibodies as analytical tools 
In this thesis, we have used antibodies against Cx43, Panx1, GSK-3β and AKT. Antibodies 
have been used in Western blot, immune-electron microscopy and immunofluorescence 
microscopy, and are made to recognize specific proteins or part of proteins (epitopes). The 
quality of antibodies differs. In some cases, the producers have incomplete information about 
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the sequence or specificity. Antibodies may bind to other proteins with similarities in a 
sequence to the protein we examined, which may lead to difficulty in analysing the results. 
We have attempted to reduce this problem by using more than one antibody against each 
protein and with the use of positive and negative controls in our experiments.  
 
Western blot was used to study protein expression and changes in the phosphorylation of 
proteins, and was performed on extracts from isolated hearts, cells in culture and isolated 
mitochondria. The phosphorylation status is quickly lost during the preparation of cells and 
tissue, so to examine phosphorylation demands the use of protease inhibitors, and when 
working with isolated hearts there is a need for quick cooling by use of liquid nitrogen and 
freeze clamping to avoid dephosphorylation. This method is a semi-quantitative amplification 
reaction since it is based on chemiluminescence reaction coupled to the binding of an 
antibody.  
 
Immune-electron microscopy was performed on samples from isolated hearts, with both a 
formaldehyde fixation and high-pressure freezing technique being used. Formaldehyde 
fixation was used to fixate samples for Cx 43 detection. Panx1 detection did not work in 
formaldehyde fixation, most likely because formaldehyde blocks Panx1 antibodies from 
attaching to the Panx1 protein; thus, we had to use high-pressure freezing fixation to detect 
Panx1. Tissues were ultra cryosliced and the antibody was used on 70 nm thick slices. The 
secondary antibody was gold particles (5nM), and we used negative controls without primary 
antibodies to check the sensitivity for gold particles. All primary antibodies were tested in a 
dose-dependent manner and we chose the lowest concentration for detection.    
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3.5 Chemical compounds as experimental tools   
Pharmacological treatment and the use of blockers against enzymes, receptors and channels 
demonstrate the same challenge as for antibodies. Heptanol is an unspecific gap junction 
uncoupler, but may also affect other channels and pumps. Heptanol is a long-chain alcohol 
that causes closing of the gap junction channels by decreasing the fluidity of cholesterol-rich 
domains in the membrane. Gap26 mimetic peptide is a more specific blocker, and is derived 
from the first extracellular loop sequence of Cx 43. This short mimetic peptide reversibly 
inhibits gap junction and Cx43-hemichannels (Anaspec).10Panx1 is also a mimetic peptide, 
but this peptide blocks Panx1-hemichannels (Anaspec). However, there are indications that 
even these small mimetic peptides may not be specific [57].  
  
Hydrogen sulfide is a very difficult substance to handle because it is a gasotransmitter and its 
half-life is very short (only seconds in plasma). As a result, it has been proven to be difficult 
to measure the concentration of this gas in a buffer or serum. In this thesis, we have used 
sodium hydrosulfide (NaHS #161527 Sigma-Aldrich) as an exogenous hydrogen sulfide 
donor. Hydrogen sulfide is generated by the spontaneous dissociation of the hydrogen sulfide 
donor NaHS in aqueous solution according to the equations:  
 
This compound contains approximately 28-32% water according to the supplier, though the 
water content may increase when the cap is opened. When the NaSH is added to the buffer, 
some hydrogen sulfide will always diffuse to the air and the concentration of hydrogen sulfide 
is reduced over time (see Discussion). A good donor for the exogenous delivery of hydrogen 
sulfide is still lacking. We therefore developed a method to measure hydrogen sulfide in the 
buffer: To measure hydrogen sulfide in the buffer, we used a modification of the method of 
 25
W-J Cai et al. [58]. Briefly, 1.0 ml of the sample to be measured (buffer) was added to 0.125 
ml 1% zinc acetate in tightly sealed Eppendorf tubes. The resulting precipitate was dried 
under 2 millibar of vacuum using a Speed Vac SC-210A concentrator (Thermo Scientific), 
followed by the addition of 0.375 ml water. Next, 0.067 ml of 20mM N,N-dimethyl-
phenylenediamine dihydrochloride in 7.2 M HCl was added, which was followed by the 
addition of 0.067 ml of 30mM FeCl3 in 1.2mM HCl. After 30 min of incubation in the dark, 
the absorbance of the resulting Methylene blue solution was measured at 670 nm against a 
calibration curve of NaHS (0.1-2.5 mM).  
 
Dithionite is a chemical compound which is a strong reducing agent and acts as an oxygen 
scavenger and rapidly reduces oxygen content in an oxygen-containing buffer. In a given 
culture medium one can not exclude that also other components in the buffer will be reduced. 
There are also indications that dithionite may cause reduction of electron transfer proteins 
directly in the mitochondria [59]. 
 
Glibenclamide, 5HD and paxilline have all been used to block various potassium channels. 
Glibenclamide is a sulfonylurea derivate that was originally developed in 1966 as an 
antidiabetic drug. It is known to block both sarcolemmal and mitochondrial ATP-dependent 
potassium channels in pancreatic beta cells, but this effect was also shown in cardiac cells 
[60]. 5HD is a natural lipid in milk that is proposed to be a specific blocker for mitoKATP-
channels [61], although one report claims that 5HD also blocks sarcolemmal KATP-channels 
[62]. Paxilline is an indole alkaloid produced by Penicillium paxilli, and is known to block 
mitoKCa-channels [63].        
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3.6 Mitochondrial isolation and respiration 
The method used for mitochondria isolation and the measurement of respiration is described 
in Paper 2. Mitochondrial isolation and the fraction of mitochondria into SSM and IFM have 
also been used in Paper 4, though the purity of the mitochondria fraction could be a problem. 
We have tried to verify the purity of our mitochondrial fraction by using antibodies against 
NaK-ATPase and VDAC. Cx43 was found in the mitochondria, but only in SSM fraction and 
not in the IFM fraction. Immune-electron microscopic pictures of the heart have showed Cx43 
detection both in SSM and IFM. The standard protocol for separating SSM and IFM is that 
the IFM fraction is added trypsin. Our observations that Cx43 is only detected in SSM and not 
IFM lead us to the hypothesis that maybe trypsin itself removes Cx43 in the IFM fraction. By 
adding trypsin to the SSM fraction there is no longer detection of Cx43 (Figure 3.6).    
 
 
Figure 3.6: Western blot showing that Cx43 is not detected if trypsin is added to the buffer.   
 
3.7 Time to the MPTP opening in isolated myocytes 
Zorov et al. 2000 and Juhaszova et al. 2004 have described this technique [64; 65]. Isolated 
myocytes are loaded with tetramethylrhodamine (TMRM), and because of the positive charge 
of TMRM, it will accumulate in the mitochondria. The mitochondria are then exposed to laser 
light, and the TMRM molecules generate ROS. The time to the MPTP opening is calculated 
as the average time from laser exposure until the selected array of mitochondria have lost their 
membrane potential. By using this technique we can simulate ischemia-reperfusion, such as 
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conditions in the mitochondria, and examine the effect of pharmacological interventions on a 
mitochondrial level. Findings should be confirmed in an intact organ (heart) or animal using 
an endpoint-like infarct after ischemia-reperfusion in order to draw conclusions about 
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5. SUMMARY OF RESULTS 
Gap junction intercellular communication and hemichannel permeability are affected by 
ischemia. In Paper 1, GJIC and hemichannel permeability were examined in rat neonatal 
cardiac fibroblast when exposed to simulated ischemia. Figure 5.1 A shows that GJIC is 
rapidly reduced (15-30 min) when the cells are exposed to simulated ischemia, while Figure 
5.1 B shows that hemichannel opening occurs later (90-120 min) and that hemichannel 
opening correlates with reduced cell viability (Figure 5.1 C).     
 
 
Figure 5.1: A) Number of dye-containing cells after microinjection of Lucifer yellow, B) Opening of 
hemichannels calculated as percent Lucifer yellow containing cells when LY was added in the buffer 2 min 
before the end of the experiment, C) Cell viability when cells were exposed to simulated ischemia. Modified 
HEPES buffer without dithionite (open bar), with 0.25 mM dithionite (light grey bar), 0.75 mM (dark grey bar) 
and with 2.5 mM (black bar).   
 
 A reduction in GJIC was not correlated to cell viability, but there was a good correlation to 
changes in the Cx43 phosphorylation pattern (Figure 5.2). GJIC was reduced significantly 
after 30 minutes, and as Figure 5.2 II and III shows, there is a shift from phosphorylated Cx43 





Figure 5.2: The cells were exposed to a modified HEPES buffer and dithionite as indicated (0 mM to 2.5 mM 
dithionite). Modified HEPES buffer without dithionite (open bar) n=4, with 0.25 mM (light grey bar) n=2, 0.75 
mM (dark grey bar) n=4 and with 2.5 mM dithionite (black bar) n=4. Results are shown as densitometric 
quantification and are normalized to 30 min modified HEPES buffer with 0 mM dithionite; I) Western blot with 
antibody that recognizes all phosphovariants of Cx43; II) WB with antibody that recognizes only non-
phosphorylated Cx43; III) WB with antibody that recognizes only phosphorylated Cx43, and IV) shows 
representative Western blot.  
   
These results documented that Cx43 phosphorylation is important in the regulation of GJIC 
and that hemichannel permeability is associated with a loss of cell viability. In addition, 
recent publications have indicated that Cx43 is also localized in mitochondria. We have 
confirmed these findings with both WB and immune-electron microscopy (Figure 5.3). These 
findings led to the hypotheses that Pannexin 1 (another channel protein) could be present in 
the mitochondria. Paper 4 shows for the first time that Panx1 is localized in the mitochondria 
in rat heart cells, and that Panx1 is found in both the SSM and IFM fraction. There was no 
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detectable Panx1 in neonatal rat cardiac myofibroblasts tested by WB, although there was also 
significant expression at the gen level (mRNA) in these cells.  
 
 
 Figure 5.3: Representative Western blots showing Cx43 in left ventricle (LV) and in mitochondria, especially in 
SSM.  Panx1 are found in both mitochondria fractions, but in higher concentrations of Panx1 in SSM compared 
to IFM. Na/K-ATPase and VDAC were tested to confirm the purity of the mitochondrial fractions.  
 
Against the background that GJIC is rapidly reduced during simulated ischemia and that 
ischemic preconditioning is very cardioprotective, we tested whether cyclic pretreatment with 
the gap junction uncoupler Heptanol was cardioprotective. We used isolated perfused rat 
hearts, and the treatment was 10 min of 2 mM Heptanol and 5 min of reperfusion three times 
before prolonged regional ischemia and 2 hours of reperfusion. The proposed cardioprotection 
was confirmed with a 58% reduction in infarct/risk volume (Figure 5.4). Heptanol also 
significantly increased the time to the MPTP opening in TMRM-loaded cardiac myocytes 
when tested using the line scan mode of the confocal microscope. The increased 
phosphorylation of AKT and GSK-3β as well as the opening of mitoKATP- and mitoKCa-
channels were proposed as the underlying mechanism for this cardioprotection, and since we 
were able to demonstrate reduced mitochondrial respiration, the mechanism triggering 
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cardioprotection was most likely related to mitochondrial function and not to the cell to cell 
coupling.   
 
 
Figure 5.4: Isolated perfused rat hearts with 30 minutes of regional ischemia and 2 hours of reperfusion. Each 
open circle represents one heart, and a filled circle with error bars represents means ± SEM. 
 
The opening of the mitoKATP-channels is known to be cardioprotective, and as we showed 
with heptanol, the blocking of the mitoKATP-channels abolished the cardioprotection given by 
heptanol. In 2005, there were reports which indicated that the new gasotransmitter hydrogen 
sulfide causes the relaxation of smooth muscle of different types and that glibenclamide (KATP 
blocker) abolishes this effect. Glibenclamide is also an effective blocker of IPC. Against this 
background, we tested whether the new gasotransmitter hydrogen sulfide was 
cardioprotective, and found that with a specific concentration (1 μM), the infarct/risk volume 
was reduced by 50% and that this effect was abolished by blocking both KATP-channels, and 
most importantly, mitoKATP-channels (Figure 5.5). This was the first study to demonstrate that 





Figure 5.5: Isolated perfused rat hearts with 30 minutes of regional ischemia and 2 hours of reperfusion. Each 
open circle represents one heart, and a filled circle with error bars represents means ± SEM. 
 
We have also attempted to use exogenous hydrogen sulfide as post-treatment and 
postconditioning, but have failed to show cardioprotection (data not shown). The new method 
developed for analysing hydrogen sulfide indicates that the concentration of hydrogen sulfide 
is rapidly reduced by time and that gassing the buffer with CO2/O2 increases the evaporation 
of gas, thereby reducing the concentration in the buffer. When we were using hydrogen 
sulfide after ischemia the buffer with hydrogen sulfide had been bubbled for approximately 1 
hour and the concentration of hydrogen sulfide was very low. This could be the explanation 
for why we do not get cardioprotection when we tried to give hydrogen sulfide after the 
ischemic period. Consequently, we cannot conclude that treatment with hydrogen sulfide 
lasted for 50 minutes, but we must conclude that we have shown the effect of treatment only a 
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Figure 5.6: Results from two separate experiments in which we measured the concentration of hydrogen sulfide 
over time in KHB during bubbling with CO2/02. 
  
After a prolonged time (90-120 min) exposure to simulated ischemia, neonatal heart 
fibroblasts opened hemichannels and cell viability was therefore reduced. By adding heptanol 
or Gap26, the opening of hemichannels was abolished or decreased in these cells. We then 
hypothesized that by keeping hemichannels closed during ischemia-reperfusion, the infarct 
size could be reduced. We used isolated perfused rat hearts and added Gap26 or 10Panx1 to 
the 2 latest min of regional ischemia and 10 min into reperfusion. By adding Gap26 the 
infarct/risk volume was reduced by 60%, although 10Panx1 did not change the infarct/risk 
volume. These results show that inhibiting the opening of Cx43-hemichannels during early 
ischemia-reperfusion injury reduces cell death.   
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Figure 5.7: Isolated perfused rat hearts with 30 minutes of regional ischemia and 2 hours of reperfusion. Each 


















6. GENERAL DISCUSSION 
The present thesis has displayed different routes to cardioprotection, with a focus on gap 
junction, hemichannels and mitochondria. GJIC and hemichannel permeability have been 
examined under simulated ischemia. GJIC is quickly reduced during simulated ischemia, 
while hemichannels open during prolonged ischemia. Cx43 exhibited a rapid 
dephosphorylation during early ischemia and a gradual loss of Cx43 during prolonged 
ischemia. Cx43 has been revealed in mitochondria in addition to sarcolemma. For the first 
time, Panx1 has been demonstrated to be localized to cardiac mitochondria. Pretreatment with 
the gap junction uncoupler heptanol was shown to be cardioprotective, as well as to inhibit 
mitochondrial respiration. The possible mechanisms of protection are therefore a direct effect 
of heptanol on mitochondria, or that heptanol by transient blocking gap junctions initiates 
phosphorylation of AKT and GSK-3β and the further opening of mitoKATP- and mitoKCa-
channels. The hydrogen sulfide treatment was cardioprotective in a dose-dependent manner 
and the opening of the mitoKATP-channel was proposed as the mechanism. Inhibiting the 
opening of Cx43 hemichannels was also cardioprotective when added in the early reperfusion 
period, which shows the importance of hemichannels during ischemia-reperfusion injury. This 
thesis therefore indicates that mitochondrial mechanisms and hemichannels are both crucial 
for cardioprotection.   
 
6.1 Gap junction channels and cardioprotection 
Sundset et al. 2004 [32] showed that ischemic preconditioning improved cell survival in 
cardiac myofibroblasts and proposed that the initiating mechanism was that the IPC reduced 
GJIC before prolonged ischemia, and then that GJIC was improved immediately after the 
prolonged ischemic period, thereby resulting in improved cell survival. The present results 
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with the opening and closing of the gap junction channels, with heptanol before ischemia-
reperfusion (Paper 3), support Sundset’s finding that changes in GJIC before prolonged 
ischemia may be cardioprotective.  Nevertheless, the change in mitochondrial metabolism 
with heptanol indicates that there is also a direct effect on mitochondria of heptanol. The 
reduction in the mitochondrial metabolism we observed may indicate that heptanol reduces 
F0F1ATPsyntase since State 3 is reduced by heptanol, but there are no changes in State 4. This 
enzyme is responsible for the majority of cellular production of ATP from ADP and Pi. It is 
located in the inner mitochondrial membrane and using the proton gradient for the energy 
transfer converting ADP to ATP. It is been known also that the ATPase under some 
conditions can function in reverse mode using ATP to maintain the proton gradient [66]. 
Contessi et al. [66] have shown that a mitoKATP opener such as diazoxide enhances F0F1ATP 
synthase inhibition during ischemia, and that this mechanism is important for 
cardioprotection. Moreover, our results with heptanol support this finding. Saltman et al. 2005 
[67] have also shown that a pretreatment with heptanol is cardioprotective. There is good 
evidence that IPC activates AKT and GSK-3β, which further inhibits the opening of the 
MPTP [52; 65; 68]. A pretreatment with heptanol also acts through this pathway, and also 
increases the time to the opening of the MPTP. Based on this, it is possible that changes in 
mitochondrial function result in AKT and GSK-3β, which further inhibits the opening of the 
MPTP. The data could hence indicate that there is a two-way communication between the 
cytosol and the mitochondria, which is important in cardioprotection. Studies using the 
mitoKATP opener diazoxide support this view [69], and Juhaszova et al. [70] proposed in 2009 
that mitoKATP channels opens during protection triggers and further activate PKC which give 
a positive-feedback or memory loop back to mitoKATP channels. This memory loop increases 
the activation of GSK-3β and further inhibition of MPTP.  
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6.2 Hemichannels and cardioprotection 
Shintani-Ishida et al. [71] showed that cardiomyocytes undergo a transient opening of Cx43 
hemichannels during simulated ischemia and that inhibition of the opening of these 
hemichannels was cardioprotective. In our study (Paper 1), we used cardiac myofibroblasts 
and observed an opening of the Cx43 hemichannels, though not in a transient way. We 
observed a good correlation between opening the hemichannels and reduced cell viability. 
One explanation for the difference may be that neonatal cardiomyocytes and neonatal 
myofibroblasts have a different regulation of the hemichannels during simulated ischemia. 
Shintani-Ishida et al. [71] showed an increased cell viability when they inhibited Cx43 
hemichannels with Gap26. Hawat et al. [72] used isolated perfused rat hearts and added 
Gap26 during ischemia and reperfusion, and observed a significant reduction in the 
infarct/risk ratio. These observations were supported by our finding in Paper 1, but in contrast 
to the above mentioned studies we showed that just a few minutes with Gap26 at reperfusion 
was cardioprotective. Gap 26 and 10Panx1 are newer compounds than, e.g. heptanol and are 
more specific, but these compounds have also been criticized for not being specific enough 
[57]. Our result shows that the critical period for the opening of the hemichannels is in the 
early reperfusion period. Hawat et al. 2011 (abstract) have also demonstrated that Gap26 is 
cardioprotective in an in vivo rat model with regional ischemia.      
 
6.3 Mitochondrial connexin and pannexin 
There is evidence that Cx43 is also present in the mitochondrial membrane, and is important 
for cardioprotection [35; 73; 74]. We have shown that Cx43 is present in mitochondria, 
although only in the SSM fraction of isolated mitochondria although gold immune EM 
demonstrated labelling also in interfibrillar mitochondria. It is very important to examine 
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SSM and IFM separately because recent reports have indicated that SSM can be 
preconditioned, but not IFM (Presentation ISRH Haifa 2011 Ruiz-Meana). Both Boengler 
[35] and our group (Paper 3) have shown that only SSM contains Cx43, and that this may be 
the reason way IFM cannot be preconditioned. It should be noted that the difference between 
these two mitochondrial fractions has to be addressed within the perspective of the use of 
different isolation protocols to obtain the two fractions. We have showed (figure 3.6) that the 
uses of trypsin removes Cx43, and indirectly that the use of trypsin onto IFM would make a 
false negative answer. However, this finding also adds to the good evidence for a link 
between mitochondrial Cx43 and preconditioning.  
 
Vessey et al. [45; 46] have indicated that Panx1 channels are important, both during ischemic 
preconditioning and postconditioning in isolated rat hearts. They have also revealed by 
Western blot that Panx1 is expressed in the heart. They have shown that the blocking of 
Panx1 channels with carbenoxolone and other unspecific blockers abolish pre- and 
postconditioning. The present results (Paper 4) show that Panx1 is expressed in rat heart, but 
that the subcellular localization is in the mitochondria and not in the sarcolemma under 
normal conditioning. This is in contrast to what has been proposed for astrocytes, in which 
studies might indicate localization in or close to the cell membrane. The blockers Vessey et al. 
[45; 46] used may affect other channels, especially Cx43 gap junction channels or Cx43 
hemichannels that are important during pre- and postconditioning. Another explanation may 
be that Panx1 changes localization during different stimuli such as ischemia or 
pharmacological treatment. In Paper 1, we showed that 10Panx1 did not close hemichannels 
during simulated ischemia in cell cultures, and that the infarct/risk ratio in the rat heart was 
not changed by adding 10Panx1 in the early ischemia-reperfusion period. The physiological 
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and pathophysiological function of Panx1 in heart and cardiac mitochondria is still not clear, 
and needs further examination.     
 
6.4 Hydrogen sulfide 
Paper 2 in this thesis provided the first evidence that exogenous hydrogen sulfide can limit 
infarct size, and that this protection was dependent on the mitoKATP-channel [53]. The present 
thesis indicates that H2S can insert a preconditioning like effect. Later studies have shown 
cardioprotection by both exogenous and endogenous hydrogen sulfide, both in vitro and in 
vivo [49; 75; 76]. Recent studies suggest that hydrogen sulfide may be important during 
IPOST as well as IPC [75; 76; 77; 78].  
 
7. MAIN CONCLUSION 
Simulated ischemia rapidly reduced GJIC, thereafter leading to the opening of Cx43 
hemichannels. GJIC was associated with a shift from phosphorylated Cx43 to non-
phosphorylated Cx43, and the hemichannel opening was associated with reduced cell 
viability.  
 
Cx43 is present in the mitochondrial, and heptanol increases the time to the opening of the 
MPTP. Panx1 is also present in the mitochondria in the heart, but not in the sarcolemma The 
blocking of Panx1 channels in heart-derived cells, or in the heart, does not changes 
hemichannel permeability or infarct size when added in the early ischemia-reperfusion period.  
 
A pretreatment with heptanol is cardioprotective, with the mechanism relying on the 
phosphorylation of AKT/GSK-3β and on the opening of the mitochondrial potassium 
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channels. Exogenous hydrogen sulfide is cardioprotective in a dose-dependent manner and the 
mechanism also relies on the opening of the mitochondrial potassium channels. Inhibition of 
the Cx43 hemichannel opening during the early ischemia-reperfusion is cardioprotective, and 
may be a future way to reduce ischemia-reperfusion injury in patients. 
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